OmniAb, Inc. (NASDAQ:OABI - Get Free Report) CEO Matthew W. Foehr sold 19,382 shares of the firm's stock in a transaction dated Monday, April 7th. The shares were sold at an average price of $2.00, for a total value of $38,764.00. Following the sale, the chief executive officer now owns 3,796,236 shares of the company's stock, valued at $7,592,472. This represents a 0.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
OmniAb Stock Up 4.3 %
NASDAQ:OABI traded up $0.08 during trading hours on Friday, reaching $1.93. 851,877 shares of the stock were exchanged, compared to its average volume of 559,772. The stock has a market capitalization of $235.72 million, a P/E ratio of -3.11 and a beta of 0.06. The firm has a 50 day simple moving average of $2.99 and a 200-day simple moving average of $3.52. OmniAb, Inc. has a 52 week low of $1.81 and a 52 week high of $5.25.
OmniAb (NASDAQ:OABI - Get Free Report) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. The firm had revenue of $10.80 million during the quarter, compared to the consensus estimate of $10.13 million. OmniAb had a negative net margin of 308.78% and a negative return on equity of 20.97%. During the same quarter in the previous year, the company posted ($0.14) earnings per share. As a group, analysts expect that OmniAb, Inc. will post -0.61 earnings per share for the current year.
Analysts Set New Price Targets
A number of brokerages recently commented on OABI. Benchmark reduced their price target on OmniAb from $8.00 to $6.00 and set a "buy" rating for the company in a report on Thursday, March 20th. HC Wainwright restated a "buy" rating and issued a $11.00 price target on shares of OmniAb in a research note on Wednesday, March 19th. Finally, Royal Bank of Canada reduced their price objective on shares of OmniAb from $7.00 to $4.00 and set an "outperform" rating on the stock in a research note on Thursday, March 27th.
Get Our Latest Analysis on OmniAb
Institutional Investors Weigh In On OmniAb
A number of institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. grew its stake in OmniAb by 582.1% during the 4th quarter. JPMorgan Chase & Co. now owns 1,001,797 shares of the company's stock worth $3,546,000 after buying an additional 854,929 shares during the last quarter. Royce & Associates LP lifted its position in OmniAb by 438.6% in the 4th quarter. Royce & Associates LP now owns 707,080 shares of the company's stock valued at $2,503,000 after purchasing an additional 575,796 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in OmniAb by 4.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,025,674 shares of the company's stock valued at $10,711,000 after purchasing an additional 142,513 shares during the period. Northeast Financial Consultants Inc bought a new position in OmniAb in the 4th quarter worth about $393,000. Finally, Barclays PLC grew its holdings in OmniAb by 321.5% in the 3rd quarter. Barclays PLC now owns 143,215 shares of the company's stock worth $606,000 after buying an additional 109,236 shares in the last quarter. Institutional investors own 72.08% of the company's stock.
About OmniAb
(
Get Free Report)
OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.
Read More
Before you consider OmniAb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.
While OmniAb currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
